直到2023年12月8日,Solvay SA/NV拥有并控制了专业聚合物,复合材料,NoveCare,技术解决方案,香气性能以及石油和天然气解决方案业务(“专业业务”),以及苏打灰和衍生物,过氧化物,过氧化物,硅胶,硅胶,特殊的Chem and Coatis Business(“基本业务”)。Effective December 9, 2023, the Specialty Businesses were separated from Solvay through a partial demerger of the Company, whereby the shares and other interests held by the Company in the legal entities operating the Specialty Businesses, the Company's rights and obligations under the agreements entered into with those legal entities, as well as certain other assets and liabilities were contributed to Syensqo, and ordinary shares of Syensqo were issued and allocated directly to索尔维的股东以比例为基础。与部分人有关,Syensqo成为一家公开上市的公司,独立于Solvay,其普通股交易在布鲁塞尔和巴黎的Euronext市场上进行。Solvay的普通股仍在布鲁塞尔和巴黎的EuroNext市场上列出。
* 通讯作者 Sunil J. Advani,加利福尼亚大学圣地亚哥分校摩尔斯癌症中心放射医学与应用科学系,3855 Health Sciences Drive, MC 0843,拉霍亚,CA 92093-0843,电话:858-822-6046,传真:858-822-5568,sjadvani@ucsd.edu。#contributed 同等贡献 作者声明 Dina V. Hingorani:调查、可视化、撰写 - 原始草稿。Jessica L. Crisp:调查、可视化。Matthew K. Doan:调查。Maria F. Camargo:调查。Maryam A. Quraishi:调查。Joseph Aguilera:调查。Mara Gilardi:调查。Larry A. Gross:方法论、调查。Tao Jiang:方法论、调查。Wei T. Li:调查。Weg M. Ongkeko:数据管理。 Ezra EW Cohen:资源、写作-评论和编辑。J. Silvio Gutkind:资源、写作-评论和编辑。Stephen R. Adams:方法论、资源、写作-评论和编辑。Sunil J. Advani:概念化、写作-原始草稿、监督、资金获取。
自动化气象 - 冰 - 地球物理学 - 海洋观察系统(Amigos)是一种多传感器的冰上海洋,冰和气候观测系统,设计系统,可在全年实时实时进行极端和遥远的部署,与最小的人类交互。工程和软件需求相对独特且具有挑战性,但与其他领域的探索非常相似。Partnering with the CU chapter of the Colorado Space Grant Consortium (COSGC), a NASA funded organization for creating opportu- nities and learning experience for Colorado students interested in careers in space technology, a group of CU undergraduate engineering students known as the Junior Antarctic Engineering Team (JANE) was formed and contributed start to finish in the development of the latest iteration of these sys- tems, the AMIGOS iii。在2020年初,这项工作最终在南极的东部Thwaites冰架上安装了两个Amigos III,在Cavyy Camp(75.048°S,105.584°W)和Channel Camp(75.057°S,75.057°S,105.446°W),约4 km相距4 km。
* 通讯作者:Dawn Neumann,dmneuman@iupui.edu。作者贡献 Dawn Neumann:参与研究设计和数据解释,并领导稿件介绍和方法部分,并帮助编辑和修改稿件的其他部分 Flora M Hammond:参与研究设计和数据解释,并帮助编辑和修改稿件的所有部分 Angelle Sander:参与研究设计和数据解释,并领导稿件讨论部分,并帮助编辑和修改稿件的其他部分 Surya Sruthi Bhamidipalli:参与数据分析、结果撰写和表格制作。 Susan M Perkins:参与研究设计、数据解释、数据分析、分析和结果部分的撰写,以及编辑和修改论文的所有部分。
Mannan Bhola, 1 , 2 , 8 Kouki Abe, 1 , 2 , 8 Paola Orozco, 3 Homa Rahnamoun, 3 Pedro Avila-Lopez, 1 , 2 Elijah Taylor, 4 Nefertiti Muhammad, 1 , 2 Bei Liu, 6 Prachi Patel, 1 , 2 John F. Marko, 4 Anne C. Starner, 5 Chuan He, 6 , 7 Eric L. Van Nostrand,5 Alfonso Mondrago´n,4和Shannon M. Lauberth 1,2,2,2,9, * 1 Simpson Querrey Querrey Epecenetics,Feinberg医学院,西北大学,芝加哥,伊利诺伊州60611,美国60611,美国2 of Molecular Biology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA 4 Department of Molecular Biosciences, Northwestern University, Evanston, IL 60208-3108, USA 5 Verna & Marrs McLean Department of Biochemistry & Molecular Pharmacology and Therapeutic Innovation Center, Baylor College of Medicine, Houston, TX, USA 6 Department of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA 7 Howard Hughes Medical Institute, The University of Chicago, Chicago, IL 60637, USA 8 These authors contributed equally 9 Lead contact *Correspondence: shannon.lauberth@northwestern.edu https://doi.org/10.1016/j.molcel.2024.07.032
Michael L. Nosella, 1 , 2 , 7 Tae Hun Kim, 1 , 2 , 3 , 4 , 7 , 8 Shuya Kate Huang, 1 , 2 , 3 , 4 Robert W. Harkness, 1 , 2 , 3 , 4 Monica Goncalves, 5 Alisia Pan, 1 Maria Tereshchenko, 2 Siavash Vahidi, 5 John L. Rubinstein, 1 , 2 , 6 Hyun O. Lee,2 Julie D. Forman-kay,1,2 *和Lewis E. Kay 1,2,2,2,2,3,4,9,9, * 1分子医学计划,生病儿童医院,多伦多,多伦多,M5G 0A4,加拿大2,加拿大2,多伦多,多伦多大学,多伦多大学,M5S 1A8,M5S 1A8,CANACE 3,MI5 STRON,MI5 SORICL STRONT,ME5 ME5 STRONICK MIRECTO 1A8, Canada 4 Department of Chemistry, University of Toronto, Toronto, ON M5S 1A8, Canada 5 Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada 6 Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 1A8, Canada 7 These authors contributed equally 8 Present address: Department of Biochemistry, School of Medicine, Case Western Reserve University,克利夫兰,俄亥俄州44106,美国9铅联系 *通信:forman@sickkids.ca(j.d.f.-k.),lewiskay@utoronto.ca(l.e.k.)https://doi.org/10.1016/j.molcel.2023.12.019
是由整个SMT委托的输入和由SMT工具的开发人员和用户组成的三个国际工作组的输入开发的:由C. Tinelli和SMT-Logic工作组主持的SMT-API工作组,由C. Tinelli和SMT模型工作组领导,由C. Barrett领导。版本2.0文档由C. Barrett,A。Stump和C. Tinelli撰写。Particular thanks are due to the following work group members, who contributed numer- ous suggestions and helpful constructive criticism in person or in email discussions: Nikolaj Bjørner, Sascha Boehme, David Cok, David Deharbe, Bruno Dutertre, Pascal Fontaine, Vi- jay Ganesh, Alberto Griggio, Jim Grundy, Paul Jackson, Albert Oliveras, Sava Krsti´c,Michal Moskal,Leonardo de Moura,PhilippRümmer,Roberto Sebastiani和Johannes Waldmann。也要感谢David Cok,Morgan Deters,AndersFranzén,Amit Goel,Jochen Hoenicke和Tjark Weber提供有关标准的其他反馈,以及Jochen Hoenicke,PhilippRümmer,PhilippRümmer,以及David Cok的仔细校对版本2.0版本的版本2.0版。
Zhenghao Lu, 1,4 Ailing Zhong, 2,4 Hongyu Liu, 2,4 Mengsha Zhang, 2,4 Xuelan Chen, 2 Xiangyu Pan, 2 Manli Wang, 2 Xintong Deng, 2 Limin Gao, 3 Linyong Zhao, 1 Jian Wang, 2 Yi Yang, 2 Qi Zhang, 2 Baohong Wu, 2 Jianan Zheng, 2 Yigao Wang, 1 Xiaohai Song, 1 Kai Liu, 1 Weihan Zhang, 1 Xiaolong Chen, 1 Kun Yang, 1 Xinzu Chen, 1 YingLan Zhao, 2 Chengjian Zhao, 2 Yuan Wang, 2 Lu Chen, 2 Zongguang Zhou, 1 Jiankun Hu, 1, * Yu Liu, 2, * and Chong Chen 1,5, * 1 Gastric Cancer Center and Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China 2 State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China 3 Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China 4 These authors contributed equally 5 Lead contact *Correspondence: hujkwch@126.com (J.H.), yuliuscu@scu.edu.cn (Y.L.), chongchen@scu.edu.cn (C.C.)
12/2024 SFB TRR 352初中咖啡休息时间,Tübingen和慕尼黑(Talk)11/2024沃里克大学(研讨会谈话)统计机制研讨会(研讨会)10/2024伦敦国王学院的无序系统研讨会(研讨会)(研讨会)(研讨会)10/2024 CQIF SEMINAR TALKBRIDGE(SEMAR),SEMAR,CAMAN,CAMAN,SMAN,09/24 GSSI,l'aquila(研讨会谈话)08/2024 SIQUMA24量子事物模拟会议,Schloss Dagstuhl(受邀发言人)07/2024国际数学物理学2024年国际数学物理大会,Strasbourg(贡献)(贡献)谈话03/2024 87。Jahrestagung der DPG,柏林(贡献的演讲)02/2024 Qmath Quantum午餐,哥本哈根(研讨会谈话)12/2023量子和动态圣诞节2023,米兰(邀请发言人)09/20223/2023 Oberwolfach Workshop“多人量子系统”(邀请量子)(邀请)的班级(邀请)班上的夏季夏季夏季夏季介绍,华沙(贡献)01/2023 Oberseminar Mathematische Physik,Tübingen大学(研讨会)(研讨会)11/2022 GAUS研讨会,在线(研讨会谈话)08/2022 QAINTISSIMA在Serenissima in serenissima iv,Venice,Venice,Venice,Venice(贡献)的量身定量como McqM22,Como intermecte in n serenissima iv( IQM22 Workshop I,Politecnico di Milano(演讲)02/2022 02/2022奥地利第二天的数学女性日,在线(贡献)05/2021 Mathphys Analivation Analysis研讨会,ISTA(研讨会谈话)教学
ycoplasma pneumoniae is a common etiologic agent of community-acquired pneumonia (CAP) among children. Although M. pneumoniae infection often causes a mild and self-limiting dis- ease, pneumonia develops in ≈ 10%–20% of pediatric patients ( 1 ). First-line therapies for M. pneumoniae infection are based on macrolides, a group of anti- microbial drugs widely used in outpatient settings because of their high oral bioavailability. However, overuse and indiscriminate use of macrolides have contributed to the emergence of macrolide-resistant M. pneumoniae (MRMP). Point mutations in the V region of the M. pneumoniae 23S rRNA gene have been associated with macrolide resistance ( 2 ). In recent years, prevalence of MRMP has increased and is very high in Asia (13.6%–100%) ( 2 – 4 ). Dur- ing spring/summer 2023, hundreds of children with CAP were admitted daily to each of the major hospi- tals in Hanoi, Vietnam. M. pneumoniae has emerged as the major pathogen detected in approximately one third of patients with CAP (5). We analyzed the mutations in the 23S rRNA gene of M. pneumoniae isolated from nasopharyngeal samples of pediatric CAP patients during the 2023 outbreak in Vinmec Times City Hospital, Hanoi.